- Home
- RDHL vs CMND Comparison
RDHL vs CMND Comparison
Compare RDHL & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDHL | CMND |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | Israel | Canada |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.2M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RDHL | CMND |
|---|---|---|
| Price | $0.39 | $6.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 821.0K | 23.7K |
| Earning Date | 09-30-2026 | 09-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17,592.31 | N/A |
| Revenue Next Year | $25.89 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.07 |
| 52 Week High | $1.60 | $7.16 |
Technical Indicators
Market Signals| Indicator | RDHL | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 33.24 | 66.02 |
| Support Level | N/A | $0.66 |
| Resistance Level | $0.71 | $7.16 |
| Average True Range (ATR) | 0.04 | 0.29 |
| MACD | -0.00 | -0.19 |
| Stochastic Oscillator | 3.20 | 5.05 |
Price Performance
Historical ComparisonAbout RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.